Arcturus Therapeutics (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed "significant and consistent" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.
The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.
The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.
Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.
Shares of Arcturus gained more than 2% in recent trading activity Monday.
Price: 13.61, Change: +0.28, Percent Change: +2.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。